Karyopharm Therapeutics Inc. (NASDAQ: KPTI)

Karyopharm Therapeutics Inc is a commercial stage pharmaceutical company that discovers develops and commercializes first in class cancer therapies by targeting the nuclear export protein XPO1. The company’s lead product is XPOVIO also known as selinexor an oral small molecule inhibitor of XPO1 that has received regulatory approval in the United States for specific indications in multiple myeloma and diffuse large B cell lymphoma. In addition to its approved indications Karyopharm Therapeutics Inc is advancing clinical programs for myelofibrosis endometrial cancer and additional lines of therapy in multiple myeloma to expand the use of its XPO1 inhibition platform.

The company generates revenue primarily from sales of XPOVIO in the United States and from licensing agreements that provide royalties milestone payments and reimbursement for development expenses. In 2025 total revenue amounted to 146 point one million dollars comprising 114 point nine million dollars of net product sales from XPOVIO and 31 point two million dollars of license revenue which included fifteen million dollars received from Menarini for reimbursement of development related costs.

Karyopharm Therapeutics Inc occupies a niche position as the pioneer of oral XPO1 inhibition with the first approved drug in this class giving it a first mover advantage in a targeted mechanism that is distinct from conventional chemotherapy and targeted agents. The company competes with a range of established therapies in oncology including Janus kinase inhibitors proteasome inhibitors immunomodulatory drugs monoclonal antibodies chimeric antigen receptor T cell therapies and bispecific antibodies. Its competitive advantages stem from the novel mechanism of action that enables nuclear retention of tumor suppressor proteins the oral route of administration and the demonstrated ability to combine with other treatments to potentially improve outcomes across multiple cancer types.

The company serves patients with hematologic malignancies such as multiple myeloma and diffuse large B cell lymphoma as well as patients with myelofibrosis and endometrial cancer who are treated in hospitals oncology clinics and specialty care settings. Karyopharm Therapeutics Inc collaborates with distribution partners to reach patients outside the United States including Menarini for Europe and other territories Antengene for Asia and Oceania FORUS for Canada and Promedico for Israel and surrounding regions. These partnerships together with direct sales and support teams in the United States form the basis of its customer base which includes healthcare providers payers and the patients who receive its therapies.